ReviewTropical diseases, travel medicine and vaccines2021
Vaccine market and production capabilities in the Americas.
Review in Tropical diseases, travel medicine and vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Assessing Immunization Coverage and the Negative Impact of Local Vaccine Production Cessation in Ecuador.Vaccines · 2025Article
- Oncogenic viruses rewire the epigenome in human cancer.Frontiers in cellular and infection microbiology · 2025Review
- The Imperative of Public Health Expertise in Ecuadorian Health Leadership: A Call for Competency-Based Appointments.International journal of public health · 2024Article
- COVID-19 in Latin America: A Snapshot in Time and the Road Ahead.Infectious diseases and therapy · 2023Review
- Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.PLOS global public health · 2023Article
- [Latin American participation in the scientific production of vaccines against COVID -19].Vacunas · 2022Article
- Current GMP standards for the production of vaccines and antibodies: An overview.Frontiers in public health · 2022Review
- Energy, environmental, economic and social equity (4E) pressures of COVID-19 vaccination mismanagement: A global perspective.Energy (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals' distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology.Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic.Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.